GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (NAS:BPTH) » Definitions » Price-to-Tangible-Book

BPTH (Bio-Path Holdings) Price-to-Tangible-Book : (As of Dec. 12, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Bio-Path Holdings Price-to-Tangible-Book?

As of today (2024-12-12), Bio-Path Holdings's share price is $0.7005. Bio-Path Holdings's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was $-0.19. Hence, Bio-Path Holdings's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Bio-Path Holdings's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Bio-Path Holdings's highest Price to Tangible Book Ratio was 33.59. The lowest was 0.85. And the median was 2.83.

BPTH's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.93
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Bio-Path Holdings's share price is $0.7005. Bio-Path Holdings's Book Value per Sharefor the quarter that ended in Sep. 2024 was $-0.19. Hence, Bio-Path Holdings's P/B Ratio of today is .


Bio-Path Holdings Price-to-Tangible-Book Historical Data

The historical data trend for Bio-Path Holdings's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Path Holdings Price-to-Tangible-Book Chart

Bio-Path Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 1.05 1.06 0.85 12.97

Bio-Path Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.68 12.97 - 3.54 -

Competitive Comparison of Bio-Path Holdings's Price-to-Tangible-Book

For the Biotechnology subindustry, Bio-Path Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Path Holdings's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's Price-to-Tangible-Book falls into.



Bio-Path Holdings Price-to-Tangible-Book Calculation

Bio-Path Holdings's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2024 )
=0.7005/-0.192
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Bio-Path Holdings Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Bio-Path Holdings's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Path Holdings Business Description

Traded in Other Exchanges
N/A
Address
4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Executives
Aline Sherwood director 347 BRANDYWINE DRIVE, IRWIN PA 15642
Tamaro Martina Molsbergen director 1307 SUMMERHILL DRIVE, MALVERN PA 19355
Mark P Colonnese director 4674 ANDREA POINTE, MARIETTA GA 30062
Peter Henry Nielsen director, officer: President, CEO & CFO 20651 PRINCE CREEK, KATY TX 77450
Paul Aubert director 4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE TX 77401
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Heath Cleaver director 4010 BALSAM FIR LN., SPRING TX 77386
Ulrich W. Mueller officer: COO & Secretary 17841 6TH AVE NW, SHORELINE WA 98177
Amy Sing director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Michael J. Garrison director 2626 SOUTH LOOP, SUITE 180, HOUSTON TX 77054
Douglas P Morris director 550 MADISON AVENUE, SUITE 3206, NEW YORK NY 10022
Gillian C Ivers-read director C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Thomas E Garrison director P O BOX 150248, OGDEN UT 84415